Galmed Pharmaceuticals Ltd. sell stratec
Start price
16.02.18
/
50%
€6.16
Target price
16.02.18
€3.88
Performance (%)
-11.57%
End price
16.02.18
€5.45
Summary
This prediction ended on 16.02.18 with a price of €5.45. The prediction for Galmed Pharmaceuticals Ltd. closed with a convincing performance of -11.57%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd. | - | - | - | - |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by stratec for this prediction
In the thread Galmed Pharmaceuticals Ltd. diskutieren
stratec stimmt der fundamentalen Bewertung mit dem Ergebnis 'überbewertet' zu
stratec stimmt am 16.02.2018 der fundamentalen Bewertung mit dem Ergebnis überbewertet zu.
Considering the 40% drop in share price, this may represent a GLMD buying opportunity for the bottom feeders, once the noise shakes out. However, given that Aramchol is its main drug in development, I would be quite wary of moving forward with the company at this time.
(Vom Mitglied beendet)